David Hauser has been working in drug development for nearly 30 years in both biotechnology and Contract Research Organizations (CRO). 

His experience spans all phases of development, with a particular focus on Phase 1-3 studies.  His experience in early phase development is significant.  While at IQVIA, he worked with one of top CNS pharma companies to develop an innovative Phase 1 network aimed at rapidly testing clinical hypotheses using a streamlined operational framework. He has also managed numerous global, late-stage clinical programs in CNS, cardiovascular medicine, oncology and critical care.  He has held management roles outside of clinical development, including regulatory affairs (medical writing and submissions) and has been involved in the preparation of numerous NDAs.  While at IQVIA, he was Vice President and Executive Strategist for a top-10 Pharma company and oversaw the operational strategy for a large portfolio of compounds in various phases of development.  Prior to coming to Perspective Therapeutics, Dr. Hauser was the Vice President of Clinical Operations at KBP Biosciences, where he managed their portfolio of cardiovascular and infectious disease compounds.  Dr. Hauser holds a M.A. in Biology from the University of Pennsylvania and a PhD in Medical Bioscience from Cardiff University.